Amgen Releases Long-Term Enbrel Data
13th Nov 2006, 22:53 GMT
Biotech company Amgen said an ongoing study of its drug Enbrel showed patients with a spine inflammation condition had positive results, consistent with a previous late-stage study.
Amgen Releases Long-Term Enbrel Data related news:
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data — EurekAlert! - Medicine and Health
- Genzyme Increasing Research and Development and Amgen Releases Long-Term Enbrel Data — Financial News USA (OTC: FNWU)
- Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years — EurekAlert! - Medicine and Health
- Amgen arthritis drug shows sustained safety and efficacy — Pharmaceutical Business Review Latest News
- Genentech to Buy Tanox for $919M and Amgen and Wyeth's ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy — Financial News USA (OTC: FNWU)
- Medarex to Get Milestone From Amgen — Financial News News from StratCenter.com
- Medarex to Receive Milestone Payment from Amgen — Bio-Technology News from StratCenter.com
- National Kidney Foundation Launches New Phase of Kidney Early Evaluation Program (KEEP), Names Amgen Inc. KEEP Principal Sponsor — PR Newswire: All Releases
- National Kidney Foundation Launches New Phase of Kidney Early Evaluation Program, Names Amgen KEEP Principal Sponsor — Nephrology/ Dialysis News from StratCenter.com
- Medarex to Get Milestone from Amgen and Illumina to Buy Solexa For About $600M — Financial News USA (OTC: FNWU)
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress